Noxopharm Limited Overview
Noxopharm began as an oncology company built around idronoxil (Veyonda®). It is now a platform company centred on Sofra™, a proprietary oligonucleotide technology in-licensed through a long-running partnership with Melbourne's Hudson Institute of Medical Research. Sofra's short synthetic nucleic acids modulate innate-immune sensors, chiefly the Toll-like receptors TLR7 and TLR8, either dampening inflammation (autoimmunity) or amplifying immune activation (immuno-oncology, mRNA-vaccine enhancement).
The lead asset, SOF-SKN™, is a topical drug for cutaneous lupus erythematosus (CLE). It completed its first-in-human HERACLES trial in January 2026 and received supportive FDA pre-IND feedback in October 2026. A 15-patient CLE study is targeted to start in Q1 CY2027.
The company runs a lean, roughly 17-person, partnership-heavy model funded by R&D tax rebates, convertible notes and chairman-linked loans. It is materially capital-constrained: at 30 June 2026 it had A$0.29m of cash, net liabilities of A$3.65m, and A$3.85m face value of notes maturing on 2 January 2027.
Company's own description
In its FY2026 preliminary report, Noxopharm describes its principal activity in three parts:
-
clinical-trial preparation for SOF-SKN™;
-
drug development aimed at new treatments for inflammation, autoimmune diseases and cancer;
-
improving mRNA vaccines.
Its standard corporate boilerplate describes it as a clinical-stage Australian biotech. The boilerplate says the company uses in-house specialists plus strategic research partnerships to build a pipeline on two platforms:
Sofra™: inflammation, autoimmunity, mRNA drug enhancement and oncology;
Chroma™: oncology.
The company describes Sofra as a new approach to drug design. It translates new knowledge of innate biology into targeted therapeutics that give precise control over disease-relevant immune signalling. It does this with synthetic oligonucleotides that mimic the body's natural regulators of immune sensors. (Sources: Appendix 4E FY2026; June 2026 Quarterly Activities Report.)
Independent characterisation
| Revenue type | Current status (FY2026) | Historical |
|---|---|---|
| Product sales | — | None ever |
| Services | — | Minor research service fees (A$36k FY2022; A$16k FY2021) and a consulting fee receivable (A$45k, related to Audio Pixels) |
| Licensing / milestones / royalties | None received to date. This is the targeted future model | — |
| Subscription | Not applicable | Not applicable |
| Non-operating "income" | R&D Tax Incentive refundable offset of A$1.43m (FY2026); interest income | R&D Tax Incentive A$2.40m–A$5.99m p.a. (FY2022–FY2025) |
Stage and focus. Noxopharm is a discovery-to-early-clinical stage, single-segment, Australia-based drug developer. Its strategy has narrowed sharply since 2023, and the value proposition is now almost entirely the Sofra platform:
-
SOF-SKN: topical TLR7/8 inhibition for CLE and potentially other inflammatory skin diseases.
-
SOF-VAC: an additive to reduce the inflammatory reactogenicity of mRNA vaccines and medicines, and to boost self-amplifying mRNA.
-
TLR8-amplifying oligonucleotides for immuno-oncology.
-
Partner-tested assets in inhaled and targeted delivery formats.
Chroma (oncology small molecules such as CRO-67) remains in the portfolio but receives little capital.
Business model. This is a classic "develop-to-license" biotech model. The company aims to generate data packages that are commercially attractive enough to out-license or partner, rather than to commercialise itself. Evidence for this:
-
Multiple Material Transfer Agreements (MTAs) under which third parties fund their own evaluation of Sofra assets.
-
The stated goal that an IND would make SOF-SKN more attractive to industry partners.
-
CEO performance options that historically vested on a licensing deal with a large pharmaceutical company.
Revenue model.
Value chain position. The company sits at the upstream discovery and early-clinical end of the pharmaceutical value chain. It outsources manufacturing, clinical operations and regulatory consulting:
-
Clinical trial unit: Doherty Clinical Trials, Melbourne, for HERACLES.
-
CRO: Novotech, for the FDA pre-IND process.
-
Contract manufacturing of SOF-SKN (vendor not disclosed).
Core science is co-developed with the Hudson Institute of Medical Research (Prof. Michael Gantier's laboratory).
Customer types. Prospective customers are licensees, not patients or prescribers:
-
mid-size to large biopharma;
-
mRNA-vaccine developers (CSL has presented Noxopharm data);
-
drug-delivery technology companies (Tezcat Biosciences in the US; InhaTarget Therapeutics in Belgium).
Strategy
Stated strategy themes (company language paraphrased)
-
Prioritise the Sofra platform. Sofra is framed as a new way of designing drugs by turning innate-immune biology into precisely targeted therapeutics (FY2026 4E).
-
De-risk and increase the commercial attractiveness of SOF-SKN through US regulatory engagement. The company states that a successful IND would raise SOF-SKN's commercial potential and appeal to partners (ASX release 6 May 2026).
-
Use partner-funded evaluation (MTAs) to validate breadth. Counterparties bear their own costs to test Sofra assets (FY2024–FY2026 4E).
-
Extend Sofra into immuno-oncology via TLR8 amplification, alongside autoimmunity and mRNA enhancement (June 2026 quarterly).
-
Scientific validation through high-impact publications (Nature Immunology; Nature Reviews Rheumatology; bioRxiv manuscript with partners).
-
Capital discipline while exploring "a range of options" for additional capital (every quarterly report since 2025).
Initiatives in the last 24 months
| Initiative | Date | Detail | Status |
|---|---|---|---|
| HERACLES first-in-human trial (SOF-SKN) | Mid-2025 → Jan 2026 | Two-part, four-concentration safety study, Doherty Clinical Trials | Completed 21 Jan 2026 |
| Convertible note programme | Jan 2025; extended Sep 2025 | A$2.6m secured at 12%; maturity extended to 2 Jan 2027; 520k extra options to holders | Outstanding |
| 4F related-party financing | Sep 2025; Feb 2026; Jun 2026 | A$1.25m loan converted to notes; A$350k loan (repaid Mar 2026); A$400k facility (A$200k drawn) | Ongoing |
| At-the-Market facility | 27 Feb 2026 | Acuity Capital, up to A$5m to 31 Jul 2031; 15m collateral shares | Undrawn at 30 Jun 2026 |
| CEO succession | Apr 2026 | Science-led CEO (Laczka) replaces Mautner | Completed |
| US regulatory strategy | May–Oct 2026 | Novotech engaged; pre-IND request 7 Jul; feedback 8 Oct | Pre-IND complete; IND submission undated |
| SOF-SKN manufacturing | Jun quarter 2026 | Controlled-environment manufacture with QC battery, for clinical supply and stability work | Under way |
| CLE patient extension study | Announced 14 Sep 2026 | About 15 patients, Melbourne; start targeted Q1 CY27 | In preparation |
| TLR8 immuno-oncology | May–Aug 2026 | Lead oligos; humanised TLR8 model | Preclinical |
| Non-dilutive grants | Nov 2025; Jul 2026 | NSW Government TechVoucher (UNSW); grant awarded to Hudson Institute for Sofra-related project | Received / partner-held |
| Promotional and outreach programme | FY2026 | Sofra marketing to industry, clinicians and conferences (e.g. CSL presentation at Options XIII) | Ongoing |
ESG / sustainability commitments: none disclosed. Formal cost-reduction programme with targets: none disclosed in the last 24 months; the major restructuring was in 2023.
Management medium-term targets / guidance
| Milestone | Target timing | Source |
|---|---|---|
| CLE extension study start | Q1 CY2027 (subject to ethics, regulatory and contracts) | ASX release 14 Sep 2026 |
| Initial efficacy signals | Q2 CY2027 | Same |
| Full data readout | Q4 CY2027 | Same |
| IND submission | Not dated | ASX release 8 Oct 2026 |
| Phase II CLE trial start | H1 CY2028 | ASX release 8 Oct 2026 |
No financial guidance is given. The company has disclosed these clinical and regulatory timelines:
Products & Services
Noxopharm has no marketed products. The catalogue below is its development portfolio, product by product.
SOF-SKN™ (Sofra platform: autoimmune / inflammatory skin)
Description: Topical formulation of the oligonucleotide SOF-16, which inhibits TLR7/8 signalling at the skin.
Lead indication: Cutaneous lupus erythematosus (CLE). Potential follow-on indications are psoriasis and dermatomyositis.
Key data: - HERACLES first-in-human study in healthy volunteers tested four concentrations, with no relevant safety issues; completed Jan 2026.
-
Preclinical PK: skin half-life of about 3.5 days with near-zero systemic absorption at the highest HERACLES dose.
-
Ex vivo activity in blood from SLE patients and joint fluid from rheumatoid arthritis patients.
Status: - Manufacturing for future clinical supply began in the June 2026 quarter.
-
FDA pre-IND feedback was received in Oct 2026: the FDA called the Phase II design reasonable and was particularly supportive of the CMC strategy.
-
A roughly 15-patient CLE study (14 days of daily topical dosing plus 7-day follow-up; lead investigator A/Prof Amanda Saracino) is targeted to start in Q1 CY2027. Initial signals are targeted for Q2 CY2027 and full data for Q4 CY2027.
-
Phase II is targeted for H1 CY2028.
Target customer: Licensing partners in dermatology and immunology.
Pricing: Not applicable / not disclosed. The company flags a potential Orphan Drug Designation opportunity.
Sources: FY2026 4E; June 2026 quarterly; ASX releases of 6 May, 7 Jul, 14 Sep and 8 Oct 2026 (via StockWire X / InvestorPA summaries).
SOF-VAC™ (Sofra platform: mRNA vaccine and medicine enhancer)
Description: Oligonucleotide add-on designed to reduce mRNA-driven inflammation, the cause of many vaccine side effects, while preserving or improving efficacy.
Data: - Reduced mRNA-driven inflammation in an animal model (FY2024).
- Data on improving self-amplifying mRNA vaccine activity, presented by CSL at the Options for the Control of Influenza XIII conference (Washington DC, late Aug/early Sep 2026).
Status: Preclinical, partner evaluation.
Target customer: mRNA vaccine and therapeutic developers.
Sources: FY2024 4E; June 2026 quarterly; ASX release of 1 Sep 2026 (headline only).
Sofra TLR8 immuno-oncology oligonucleotides
Description: Oligonucleotides that strongly amplify TLR8 activity versus current best-in-class clinical-stage TLR8 drugs, intended to enhance chemotherapy and radiotherapy.
Data / status: - New data released 26 May 2026 (share price rose about 37% on the day).
-
A human-relevant TLR8 animal model was built in early Jul 2026.
-
Further validating studies were announced on 4 Aug 2026 and 26 Aug 2026.
-
Preclinical.
US patent: A USPTO patent covering Sofra's potential use against various cancers was received in H1 FY2026.
Sources: June 2026 quarterly; H1 FY2026 4D; InvestSMART announcement list.
Partner-tested Sofra assets
| Asset / use case | Partner | Data | Status |
|---|---|---|---|
| Oligos conjugated to Tezcat delivery system (anti-inflammatory) | Tezcat Biosciences (US) | Successful attachment and strong anti-inflammatory activity preclinically. MoU signed in Q1 CY2026 to deepen collaboration | Preclinical |
| Inhaled LNP-encapsulated oligos for lung inflammation | InhaTarget Therapeutics (Belgium) | Over 75% reduction in lung inflammation in an animal model | Preclinical |
| Other undisclosed MTAs | "Mid-size to multibillion-dollar" companies | — | Evaluation |
Sources: FY2026 4E; June 2026 quarterly; March 2026 quarterly.
Chroma™ platform (oncology)
CRO-67: Dual-cell therapy targeting pancreatic cancer cells and their stromal barrier cells.
-
Preclinical in vivo results: average 56.7% reduction in tumour volume and 48% slower tumour growth versus controls.
-
US FDA Orphan Drug Designation for pancreatic cancer (FY2024).
Brain cancer candidate: First-in-class preclinical programme with the University of South Australia, supported by a A$100,000 Tour de Cure grant (FY2024).
Source: FY2024 Appendix 4E.
Veyonda® (idronoxil, formerly NOX66) – legacy
Description: Idronoxil formulation developed as an adjuvant to chemotherapy and radiotherapy in late-stage cancers.
History: - DARRT-1 / DARRT-2 (prostate, with radiotherapy; FDA IND).
-
LuPIN (with LuPSMA; published in the Journal of Nuclear Medicine, Jan 2022).
-
CEP-2 (sarcoma, with doxorubicin; FDA IND; FDA ODD for soft tissue sarcoma).
-
IONIC.
-
The company-run DARRT-2 and CEP-2 trials were discontinued in 2023 because of recruitment challenges and cost.
Current: Drug supply to the investigator-initiated IONIC trial (secondary source).
Sources: FY2022 directors' report; FY2024 4E; roic.ai (secondary).
Financial Narrative
Basis. FY2022 figures come from audited statements. FY2023–FY2024 come from the FY2024 Appendix 4E.
All figures are A$ millions unless stated. Noxopharm has no operating revenue; its "income" is almost entirely the refundable R&D Tax Incentive, which the company accounts for as a government grant under AASB 120.
Income statement
Margins and growth. Gross, operating, EBITDA and net margins are not meaningful because there is no operating revenue. Revenue CAGR is not meaningful.
Other-income CAGR FY2022–FY2026 is about -28.3% p.a. (A$5.48m to A$1.45m). This mechanically tracks the decline in eligible R&D spend, because the refundable offset is 43.5% of eligible expenditure for FY2025–26 versus 48.5% in FY2023–24.
Commentary. The five-year profile has three phases.
Phase 1: high-burn clinical oncology (FY2022–FY2023): Total opex was A$15–17m p.a. while Veyonda ran three cancer trials (IONIC, DARRT-2, CEP-2) across the US, Europe and Australia. Reported losses of A$18.7m and A$15.1m were inflated by A$13.3m of cumulative fair-value write-downs on the Nyrada stake, as Nyrada's share price fell from 13.5c to 2.8c.
Phase 2: the 2023 pivot: Clinical trials closed and headcount was cut by about 40%. Opex fell 58% to A$7.0m in FY2024. The FY2024 loss of A$3.6m was flattered by a A$1.05m Nyrada mark-up.
Phase 3: platform-focused and debt-financed (FY2025–FY2026): - FY2025: R&D rose to A$4.3m as HERACLES preparation began.
-
FY2026: R&D fell to A$1.9m once HERACLES completed, and cash constraints bit.
-
Finance costs rose from A$0.03m (FY2024) to A$1.16m (FY2026), driven by 12%-coupon convertible notes plus accretion. These costs now equal about 24% of total operating expenses.
-
The capital structure therefore increasingly consumes resources that would otherwise fund R&D.
Balance sheet
Commentary.
-
Equity eroded from A$24.1m to a deficiency of A$3.65m over four years, with no equity raised since FY2021's placement and option exercises. Issued capital has been frozen at A$74.64m since FY2022.
-
The FY2026 balance sheet is essentially a R&D rebate receivable (A$1.43m) plus A$0.29m cash, set against A$4.57m of short-term borrowings.
-
No capitalised intangibles: all R&D is expensed, and the in-licensed Sofra IP is off-balance-sheet.
Cash flow
Commentary. FY2024's unusually low operating outflow (-A$0.68m) is a timing artefact: the company received the large FY2023 rebate (A$6.05m) while spending had already been cut. Excluding rebate receipts, gross cash operating costs fell from A$19.7m to A$5.2m over five years.
The rebate is effectively pre-spent. Each year's rebate has been pledged as security or advanced against:
-
the 4F loan in 2023;
-
Endpoints Capital in 2024;
-
the convertible notes in 2025–26, which are now secured on the FY2026 rebate.
Ratios
Ratios not meaningful or not applicable:
-
ROE: -57.5% (FY2022), -90.7% (FY2023), -49.1% (FY2024), -157.9% (FY2025). Not meaningful in FY2026 because average equity is negative.
-
ROIC: deeply negative and not meaningful.
-
Debt/equity: 0.00x to FY2024, 3.6x in FY2025, not meaningful in FY2026 (negative equity).
-
Net debt/EBITDA: not meaningful (negative EBITDA).
-
Interest coverage: negative, not meaningful.
-
Asset turnover: zero revenue.
-
Cash conversion cycle: no inventory or receivables cycle from customers; not applicable.
All ratios are derived from the filings above.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Country | Ownership | Function |
|---|---|---|---|
Noxopharm Limited | Australia | Parent (ASX-listed) | Operating company, IP holder and licensee |
Norbio Holding Pty Ltd | Australia | 100% | Holding entity (function not separately disclosed) |
Pharmorage Pty Limited | Australia | 100% | Subsidiary (historically associated with Veyonda supply); current activity not disclosed |
Results by Segment and Segment Margins & Growth (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Segment other income incl. R&D tax incentive (AUD Mn) | 2.41 | 2.83 | 1.45 |
Segment loss before tax (AUD Mn) | -3.58 | -4.88 | -4.46 |
Other income YoY growth (%) | -60.5 | 17.5 | -48.8 |
Segment loss YoY change (%) | -76.2 | 36.5 | -8.8 |
Share of group total (%) | 100 | 100 | 100 |
Platform Details
| Platform | Programmes | Stage (Oct 2026) | Resource priority |
|---|---|---|---|
Sofra™ – anti-inflammatory | SOF-SKN (topical, CLE) | Phase I complete; patient extension study targeted Q1 CY27; Phase II targeted H1 CY28 | Highest |
Sofra™ – mRNA enhancement | SOF-VAC; self-amplifying mRNA enhancer data (presented by CSL) | Preclinical | Medium (partner-led) |
Sofra™ – immuno-oncology | TLR8-amplifying oligonucleotides | Preclinical (humanised TLR8 model built in 2026) | Medium |
Sofra™ – partner-delivered assets | Tezcat conjugates; InhaTarget inhaled LNP | Partner preclinical | Partner-funded |
Chroma™ – oncology | CRO-67 (pancreatic; FDA ODD); brain cancer programme (UniSA; Tour de Cure grant) | Preclinical | Low |
Legacy – Veyonda® (idronoxil) | Supply to investigator-initiated IONIC trial | Company trials discontinued in 2023 | Minimal |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating revenue from customers (AUD Mn) | 0.04 | 0 | 0 | 0 | 0 |
R&D tax incentive income (AUD Mn) | 5.37 | 5.99 | 2.40 | 2.82 | 1.43 |
Total other income incl. interest and grants (AUD Mn) | 5.48 | 6.09 | 2.41 | 2.83 | 1.45 |
Research and development expense (AUD Mn) | 7.78 | 10.65 | 2.94 | 4.27 | 1.94 |
Consulting, employee and director expense (AUD Mn) | 5.40 | 4.18 | 2.97 | 3.00 | 2.10 |
Corporate administration expense (AUD Mn) | 1.77 | 1.67 | 1.10 | 0.94 | 0.80 |
Depreciation and amortisation (AUD Mn) | 0.26 | 0.15 | 0.00 | 0.00 | 0.00 |
Total operating expenses (AUD Mn) | 15.21 | 16.66 | 7.00 | 8.21 | 4.85 |
Operating loss before FV items and finance (AUD Mn, derived) | -9.73 | -10.56 | -4.60 | -5.38 | -3.40 |
EBITDA excl. FV items (AUD Mn, derived) | -9.47 | -10.41 | -4.59 | -5.38 | -3.40 |
Fair-value gain/(loss) on Nyrada investment (AUD Mn) | -8.86 | -4.45 | 1.05 | 0.47 | 0 |
Convertible note derivative and modification FV, net (AUD Mn) | 0 | 0 | 0 | 0.53 | 0.10 |
Finance costs (AUD Mn) | 0.08 | 0.04 | 0.03 | 0.50 | 1.16 |
Pre-tax loss (AUD Mn) | -18.67 | -15.06 | -3.58 | -4.88 | -4.46 |
Income tax (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Net loss (AUD Mn) | -18.67 | -15.06 | -3.58 | -4.88 | -4.46 |
Basic and diluted EPS (A$ cents) | -6.41 | -5.15 | -1.22 | -1.67 | -1.50 |
Dividends per share (A$ cents) | 0 | 0 | 0 | 0 | 0 |
Weighted average shares (millions) | 291.22 | 292.24 | 292.24 | 292.24 | 292.24 |
Balance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash and cash equivalents (AUD Mn) | 14.01 | 3.01 | 2.32 | 1.55 | 0.29 |
R&D rebate receivable (AUD Mn) | 5.00 | 5.98 | 2.32 | 2.81 | 1.43 |
Total current assets (AUD Mn) | 20.83 | 9.16 | 4.77 | 4.58 | 1.83 |
Financial assets at FV – Nyrada (AUD Mn) | 5.42 | 0.96 | 2.01 | 0 | 0 |
Total assets (AUD Mn) | 26.59 | 10.13 | 6.78 | 4.58 | 1.84 |
Short-term debt – convertible notes incl. derivative (AUD Mn) | 0 | 0 | 0 | 2.48 | 4.37 |
Short-term debt – unsecured related-party loan (AUD Mn) | 0 | 0 | 0 | 0 | 0.20 |
Lease liabilities (AUD Mn) | 0.16 | 0 | 0 | 0 | 0 |
Long-term debt (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Total debt (AUD Mn) | 0.16 | 0 | 0 | 2.48 | 4.57 |
Net debt (AUD Mn; negative = net cash) | -13.85 | -3.01 | -2.32 | 0.92 | 4.28 |
Total liabilities (AUD Mn) | 2.48 | 1.06 | 1.29 | 3.89 | 5.48 |
Total equity (AUD Mn) | 24.12 | 9.07 | 5.50 | 0.69 | -3.65 |
Goodwill and intangibles (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Working capital (AUD Mn) | 18.55 | 8.20 | 3.52 | 0.71 | -3.63 |
Issued capital (AUD Mn) | 74.64 | 74.64 | 74.64 | 74.64 | 74.64 |
Accumulated losses (AUD Mn) | -58.80 | -72.06 | -70.07 | -74.65 | -78.48 |
NTA per share (A$ cents) | 8.26 | 3.10 | 1.88 | 0.24 | -0.01 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Payments to suppliers and employees (AUD Mn) | -19.69 | -16.05 | -6.71 | -8.10 | -5.15 |
R&D tax rebate received in cash (AUD Mn) | 5.86 | 5.01 | 6.05 | 2.34 | 2.81 |
Operating cash flow (AUD Mn) | -13.73 | -10.95 | -0.68 | -5.82 | -2.71 |
Capital expenditure (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Free cash flow (AUD Mn) | -13.73 | -10.95 | -0.68 | -5.82 | -2.71 |
Proceeds from investments – Nyrada sale (AUD Mn) | 0 | 0 | 0 | 2.48 | 0 |
Equity issued incl. option exercise (AUD Mn) | 1.20 | 0 | 0 | 0 | 0 |
Net convertible notes and borrowings (AUD Mn) | 0 | 0 | 0 | 2.60 | 1.45 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Net change in cash (AUD Mn) | -12.76 | -11.00 | -0.68 | -0.75 | -1.26 |
Margin Analysis (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Return on assets (%, net loss / avg total assets) | -50.1 | -82.0 | -42.3 | -85.9 | -138.9 |
Current ratio (x) | 9.13 | 9.52 | 3.83 | 1.18 | 0.34 |
R&D expense as % of total opex (%) | 51.1 | 63.9 | 41.9 | 52.0 | 40.1 |
Finance costs as % of total opex (%) | 0.5 | 0.2 | 0.4 | 6.1 | 23.9 |
Gross operating cash burn excl. rebates (AUD Mn) | 19.69 | 16.05 | 6.71 | 8.10 | 5.15 |
Results by Region and Region Margins & Growth (%)
| Region | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Australia – total other income (AUD Mn) | 2.41 | 2.83 | 1.45 |
Americas – operating revenue (AUD Mn) | 0 | 0 | 0 |
EMEA – operating revenue (AUD Mn) | 0 | 0 | 0 |
APAC ex-Australia – operating revenue (AUD Mn) | 0 | 0 | 0 |
Australia income YoY growth (%) | -60.5 | 17.5 | -48.8 |
Per-Share Data
| Metric | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|
Share price at 30 June (A$ cents) | 36.5 | 61.0 | 47.5 | 16.5 | 64.5 | 19.5 | 4.3 |
Per-Share Data (FY2018–FY2022)
| Metric | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
Share price FY high (A$ cents) | 158.0 | 72.0 | 45.92 | 95.0 | 69.5 |
Share price FY low (A$ cents) | 29.0 | 35.5 | 8.39 | 18.5 | 17.5 |
Change by Horizon
| Horizon | Change | Basis |
|---|---|---|
1-year (to 28 Sep 2026) | About -39% | Investing.com |
3-year | About +40% | 30 Jun 2023 price of A$0.043 to about A$0.060 |
5-year | About -91% | 30 Jun 2021 price of A$0.645 to about A$0.060 (approximate, period-end based) |
Capital Markets
| Metric | Value (Oct 2026) | Comment |
|---|---|---|
Market capitalisation | About A$18.4–19.1m | About 307m shares including 15m ATM collateral shares |
Enterprise value | About A$22.8m | Market cap about A$18.9m + convertible notes (A$3.85m face) and 4F loan (A$0.2m) − cash (A$0.29m at 30 Jun 2026) |
EV / annual R&D spend | About 11.7x | Analyst metric (A$22.8m / A$1.94m FY2026 R&D) |
Capital Instruments
| Instrument | Face / drawn | Rate | Maturity | Security |
|---|---|---|---|---|
Convertible notes (original holders) | A$2.60m | 12% (interest capitalised from 2 Jan 2026) | 2 Jan 2027 | Secured on FY2025/26 R&D rebate |
Convertible notes (4F Investments) | A$1.25m | 12% | 2 Jan 2027 | Unsecured |
4F loan facility | A$0.20m drawn of A$0.40m | 12% capitalised | On next capital raising (no fixed date) | Unsecured |
Acuity ATM | A$5.0m limit, undrawn | — | 31 Jul 2031 | 15m collateral shares |
Analyst Conclusions
Management guidance
No financial guidance is given. Operational guidance:
-
CLE extension study to start in Q1 CY2027, with initial efficacy signals in Q2 CY2027 and full data in Q4 CY2027.
-
Phase II targeted for H1 CY2028.
-
IND submission in preparation, not dated.
Management has said in each quarter that it is reviewing the timing, method and amount of additional funding, and has noted it is weighing near-term catalysts in its funding timing (June 2026 Appendix 4C).
Consensus growth expectations: none (no coverage).
Bull case
-
Clinical proof-of-concept could re-rate the platform. If the 15-patient CLE study shows clear skin-lesion improvement in 2027 on a safe, topical, non-systemic profile, SOF-SKN becomes a partnerable asset in an indication with no specifically approved therapy. That would happen with the FDA already aligned on Phase II design and CMC, from an EV of only about A$23m.
-
Platform optionality is underpriced. At the current EV, the market ascribes little value to:
-
SOF-VAC / sa-mRNA (CSL-presented data);
-
TLR8 immuno-oncology;
-
partner-delivered assets (Tezcat, InhaTarget);
-
CRO-67 (FDA ODD). A single licence or option deal could exceed the current market capitalisation.
-
-
Lean model and R&D incentive reduce cost per milestone. Opex below A$5m p.a. with a 43.5% refundable offset means a modest raise (for example A$5–8m) could fund the CLE study and IND-enabling work.
Bear case
-
The balance sheet dictates outcomes. Net liabilities are A$3.65m, cash is A$0.29m and A$3.85m of notes plus interest fall due on 2 Jan 2027. The share price (about A$0.06) sits below the A$0.07 conversion floor. A deeply dilutive recapitalisation, a note restructuring on lender-favourable terms, or both, appears likely before the CLE study can start.
-
Competition and mechanism risk. Merck KGaA's enpatoran shares the TLR7/8 mechanism with far greater resources, and Biogen and AstraZeneca have late-stage assets in CLE. Oligonucleotide TLR antagonists have failed before (Idera). Healthy-volunteer safety says little about efficacy.
-
Governance and execution risk. The chair is also the principal lender, the board is a three-person minimum, CEO and Company Secretary changed in 2026, and the company has a history of abandoning its prior lead programme (Veyonda). Repeated near-zero cash positions reduce negotiating leverage with partners.
Key catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable |
|---|---|
| Oct–Nov 2026 | FY2026 audited accounts and auditor's going-concern language; FY2026 Annual Report; 2026 AGM resolutions (placement capacity, director elections, note terms) |
| Q4 CY2026 | Capital raising (placement / entitlement / ATM drawdowns) and terms; status of possible trading halt |
| By 2 Jan 2027 | Repayment, extension or conversion of A$3.85m notes; use of FY2026 R&D rebate (about A$1.43m) |
| Q1 CY2027 | Ethics approval and first patient dosed in CLE extension study |
| H1 CY2027 | Initial efficacy signals (Q2 CY27); IND submission timing; ODD application for SOF-SKN |
| Rolling | Partner news (Tezcat MoU conversion, InhaTarget, CSL / sa-mRNA, undisclosed MTAs); Hudson licence renewal; new patents |
| Quarterly | Appendix 4C cash, burn and related-party loans |
Analyst verdict
Noxopharm in October 2026 is a company whose science has moved forward faster than its balance sheet.
On the scientific side the progress is real. Over the past eighteen months the company has:
-
taken a novel oligonucleotide platform from preclinical concept through a clean first-in-human study (HERACLES);
-
secured publication in Nature Immunology;
-
attracted third-party validation from partners in the US, Belgium and, via conference presentation, CSL;
-
obtained FDA pre-IND feedback endorsing its Phase II design and manufacturing strategy for a topical CLE therapy.
For a company spending under A$5 million a year, that is efficient progress.
The financing structure undermines it. Equity has turned negative, cash is below one quarter's burn, and A$3.85 million of 12% notes fall due on 2 January 2027. Those notes are only partly secured by an R&D rebate already earmarked for repayment, and their conversion floor sits above the current share price. The company has funded itself since 2023 through rebate advances and, increasingly, loans from entities linked to its chairman. That has kept the lights on, but it has concentrated influence in a creditor-director, and every new milestone is negotiated from weakness.
The investment question is therefore not whether Sofra works scientifically; the early evidence is encouraging. It is whether existing shareholders will retain a meaningful share of the value if it does. A recapitalisation at or below current prices appears close to unavoidable before the CLE study can start in Q1 CY2027. Its size and terms will largely determine per-share outcomes.
Verdict: a high-risk, binary-outcome speculative situation. A credible funding package or a partnering deal, rather than further preclinical news, is the gating catalyst for any re-rating.
APPENDIX: SOURCES
Primary filings (ASX):
-
Appendix 4E FY2026 (28 Aug 2026): investorpa.com/announcement-pdf/20260828/335270.pdf
-
Appendix 4D and Interim Report H1 FY2026 (27 Feb 2026): announcements.asx.com.au/asxpdf/20260227/pdf/06wwdbdy4r929n.pdf
-
Appendix 4E FY2025 (29 Aug 2025): announcements.asx.com.au/asxpdf/20250829/pdf/06njv8b5cvnnhp.pdf
-
Appendix 4E FY2024 (29 Aug 2024): announcements.asx.com.au/asxpdf/20240829/pdf/06769r16ht7x01.pdf
-
Appendix 4E and Audited FS FY2022 (25 Aug 2022): asx.com.au/asxpdf/20220825/pdf/45d981l6f1x810.pdf
-
Appendix 4E FY2021 and FY2020: asx.com.au/asxpdf/20210826/pdf/44zsqry2f94fpt.pdf; asx.com.au/asxpdf/20200831/pdf/44m448dyjbttlj.pdf
-
Appendix 4D H1 FY2025 (25 Feb 2025): announcements.asx.com.au/asxpdf/20250225/pdf/06fxhk1crdbnbm.pdf
-
June 2026 Quarterly Activities Report and Appendix 4C (22 Jul 2026): bulletin.webull.com/qbd/announcement/20260722/499501373/2be3768cc33caead016586a3311a0128.pdf
-
Resignation of CEO (14 Apr 2026): announcements.asx.com.au/asxpdf/20260414/pdf/06yg8z0454qkqh.pdf
-
Appointment of Dr Olivier Laczka (15 Apr 2026): announcements.asx.com.au/asxpdf/20260415/pdf/06yhmbt1t28dpx.pdf
-
Pre-IND meeting request (7 Jul 2026): announcements.asx.com.au/asxpdf/20260707/pdf/071g5p923btz3b.pdf
Secondary / aggregator sources (used where flagged):
-
InvestorPA summaries (Mar 2026 quarterly; Jun 2026 quarterly; 6 May 2026 release)
-
InvestSMART (announcement lists, directors, director trades, market cap)
-
StockWire X (8 Oct 2026 FDA feedback; 14 Sep 2026 CLE study)
-
Investing.com (price, 52-week range, market cap)
-
Morningstar (employees, profile)
-
Market Index (historical FY-end prices, announcement metadata)
-
TipRanks, StockAnalysis (aggregated financials; discrepancies noted)
-
roic.ai (2023 restructuring summary)
-
MarketScreener (Laczka and Mautner profiles)
-
Finance News Network; Grafa; Biotech Dispatch; SmallCaps; Kalkine; BioWorld; IBISWorld; Pearler; Simply Wall St; financialfilings.com
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Background | Independence (assessment) |
|---|---|---|---|---|
Frederick (Fred) Bart | Non-Executive Chairman | 8 May 2020 per InvestSMART; already a director in FY2021 per filings | MD of Textile Industries Australia (1985); founder of the Bart Group (hotels, retail, property, technology); former Chairman of Electro Optic Systems (resigned Jul 2021); Chairman of Audio Pixels Holdings; director of Weebit Nano; director and majority shareholder of Immunovative Therapies (Israel) | Not independent in substance. His vehicle 4F Investments is the company's principal lender and noteholder: A$1.25m of unsecured notes plus a A$0.4m loan facility |
Peter Marks | Non-Executive Director & Deputy Chairman | 15 Mar 2016 | More than 35 years in corporate advisory, investment banking and capital markets (Australia, US, Israel). BEc, LLB, Grad Dip Commercial Law (Monash); MBA (Edinburgh). Directorships include Alterity Therapeutics; formerly Nyrada and Elsight | Nominally independent. Tenure exceeds 10 years, which ASX guidance treats as potentially affecting independence |
Boris Patkin | Non-Executive Director | 25 Mar 2020 | Investment adviser and business consultant (Morgans Financial authorised representative); BSc (Industrial Chemistry); Chairman of Ausmon Resources | Nominally independent |
Executive Leadership Team
| Name | Title | Tenure | Background / education | Remuneration (latest disclosed) |
|---|---|---|---|---|
Dr Olivier Laczka | Chief Executive Officer | Since 15 Apr 2026. Previously CSO – Inflammation; earlier Director of Drug Discovery & Research | Driving force behind the Sofra platform. Engineering degree (Ecole Supérieure d'Ingénieur de Luminy); PhD (Autonomous University of Barcelona, 2009); IUT Nantes (secondary: MarketScreener) | Fixed A$290,000 p.a. plus 12% superannuation. 2m performance options at a strike 25% above the next placement price, expiring 4 years after grant. 3-month notice (ASX release 15 Apr 2026) |
Shawn van Boheemen | Company Secretary (finance function) | Appointed about 30 Apr 2026 (replacing David Franks of Automic) | Previously provided consulting services (finance) through the company | — |
Julian Elliott | Investor, corporate and media relations | Ongoing | — | — |
Dr Gisela Mautner (former) | CEO & MD | Feb 2022 – 14/15 Apr 2026; joined 2019 as CMO | MD (TU Munich), PhD (LMU Munich), MPH (Harvard), MBA (Kellogg). Formerly Amgen, Bayer, Siemens Medical, Merck/MSD | FY2022 contract A$410,000 + 10% super. FY2022 KMP total A$833,980 (of which A$621,074 share-based) |
Dr Graham Kelly (former) | Founder; Executive Chair/CEO to Feb 2022; then NED | — | Founder of Novogen and Nyrada | FY2022 total A$408,238 |
“—” = not publicly disclosed.
Directors' Remuneration
| KMP | Cash salary/fees | Super | Share-based | Total |
|---|---|---|---|---|
Fred Bart (Chair) | 41,095 | 3,905 | 0 | 45,000 |
Graham Kelly | 384,496 | 23,742 | 0 | 408,238 |
Peter Marks | 60,000 | 0 | 0 | 60,000 |
Boris Patkin | 45,000 | 0 | 58,669 | 103,669 |
Gisela Mautner (from 1 Feb 2022) | 200,543 | 20,054 | 621,074 | 833,980 (incl. leave items) |
Total KMP | — | — | — | 1,450,887 |
Major Shareholders
| Holder (Aug 2022) | Shares | % |
|---|---|---|
Milligene Pty Ltd (GE & PR Kelly Family A/c), two lines | 35,649,106 | 12.20 |
Mrs Eleanore Goodridge | 14,121,085 | 4.83 |
RGT Capital Fund No 5 (NOXO) Pty Ltd | 6,500,333 | 2.22 |
Kale Capital Corporation Ltd | 6,255,290 | 2.14 |
Link Traders (Aust) Pty Ltd, two lines | 10,471,522 | 3.59 |
HSBC Custody Nominees (Australia) Ltd | 4,592,103 | 1.57 |
Grandor Pty Ltd (Mark Scott Family P/F) | 3,395,850 | 1.16 |
RHLC Pty Ltd | 3,300,000 | 1.13 |
Jamber Investments Pty Ltd | 3,252,762 | 1.11 |
Bart Superannuation Pty Ltd (4F Investments Superfund) | 3,080,189 | 1.05 |
Competitive Landscape
Competitors by Segment
| Area | Competitor | Asset / approach | Relative positioning vs Noxopharm |
|---|---|---|---|
CLE / lupus – TLR7/8 inhibition | Merck KGaA (Germany) | Enpatoran, oral TLR7/8 inhibitor in CLE/SLE trials | Same mechanism, systemic oral delivery, far better funded. Noxopharm differentiates on topical, skin-retained delivery |
CLE / SLE – pDC targeting | Biogen (US) | Litifilimab (anti-BDCA2 antibody), late-stage in CLE and SLE | Most advanced CLE-specific competitor; injectable biologic |
CLE / SLE – type I interferon | AstraZeneca (UK) | Anifrolumab (Saphnelo), approved in SLE; being studied in CLE | Approved product in adjacent indication; IV/SC biologic |
SLE – B-cell / BAFF | GSK (UK) | Belimumab (Benlysta), approved SLE and lupus nephritis | Standard of care in systemic disease; not skin-targeted |
SLE / CLE – TYK2 | Bristol Myers Squibb (US) | Deucravacitinib in lupus programmes | Oral small molecule; broad immunology franchise |
Lupus / autoimmune – other | Johnson & Johnson, Novartis, Roche, others | Multiple biologic and small-molecule lupus programmes | Crowded systemic lupus field |
Oligonucleotide TLR antagonists (historical) | Idera Pharmaceuticals (US) | IMO-8400 (TLR7/8/9 antagonist), discontinued in dermatomyositis | Precedent for oligonucleotide TLR modulation and its clinical risk |
TLR8 agonists – immuno-oncology / antiviral | Gilead (selgantolimod); motolimod (formerly VentiRx) | TLR8 agonists | Noxopharm claims stronger TLR8 amplification than best-in-class clinical drugs (company assertion, preclinical) |
mRNA reactogenicity / potency | Moderna, BioNTech, CSL/Arcturus (sa-mRNA), CureVac | In-house formulation, nucleoside modification, LNP optimisation | Potential partners as much as competitors; Noxopharm offers an additive |
ASX micro-cap immunology / oncology peers | Nyrada (NYR), Alterity (ATH), Kazia (KZA, Novogen successor), Immuron (IMC) | Various | Compete for the same small-cap biotech capital |
Peer Comparison FY2026
| Company | Latest FY revenue | R&D intensity | Source / status |
|---|---|---|---|
Noxopharm (FY2026) | A$0 operating revenue (A$1.45m other income) | n/m (R&D 40% of opex) | FY2026 4E |
AstraZeneca (FY2024) | about US$54.1bn | about 25% (approx.; verify against 2024 Annual Report) | AstraZeneca FY2024 annual report (figures from analyst recollection; verify) |
Biogen (FY2024) | about US$9.7bn | about 21% (approx.; verify) | Biogen 2024 Form 10-K (verify) |
Merck KGaA (FY2024) | about €21.2bn net sales | — | Merck KGaA 2024 annual report (verify) |
Recent Developments
Investors should verify the current ASX trading status directly.



